Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Can Risk-Adapted EPOCH-R Replace Intensive Therapy for Burkitt Lymphoma?

Adults with Burkitt lymphoma are typically treated with dose-intensive combination chemotherapy derived from pediatric leukemia regimens, which the study investigators noted is “acutely toxic...

FDA Approves Tazemetostat for EZH2-Mutated Follicular Lymphoma

Tazemetostat, an enhancer of zeste homolog 2 (EZH2) gene inhibitor, was granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL)...
On location

KEYNOTE-204: Pembrolizumab Superior to Brentuximab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with anti-PD-1 antibody pembrolizumab prolonged progression-free survival (PFS) more than brentuximab vedotin (BV) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R...

FDA Approves Oral Selinexor for Relapsed/Refractory DLBCL

The FDA has granted accelerated approval to selinexor for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL...

John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...
WIB_icon

Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?

Compared with the widely used International Prognostic Index (IPI) and revised IPI (R-IPI), the most recent National Comprehensive Cancer Network IPI (NCCN-IPI) better predicts...
WIB_icon

Temozolomide Demonstrates High Response in Older Patients With Primary Vitreoretinal Lymphoma

Temozolomide demonstrated a high overall response rate in a study of patients with primary vitreoretinal lymphoma (PVRL) who were either considered ineligible for intensive...

Outpatient CAR T-Cell Therapy Appears Feasible for Patients With Large B-Cell Lymphoma

According to an analysis of three studies evaluating lisocabtagene maraleucel (liso-cel) presented at the 2020 Transplantation & Cellular Therapy Meetings, treatment with the outpatient...

FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131

The FDA has granted orphan drug designations to two therapies for hematologic conditions. The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...

Tazemetostat Granted Priority Review for Relapsed/Refractory Follicular Lymphoma

The FDA granted a priority review to the new drug application (NDA) for tazemetostat for the treatment of patients with relapsed or refractory follicular...
Advertisement

Current Issue

July 2020 Bonus Mid-Year Edition, Volume 6 Issue 9

This issue features analysis of COVID-19-associated lymphopenia, coverage from the ASCO and EHA annual meetings, and more.